Another FDA letter to a stem cell clinic supplier: what’s the agency’s long game?

FDA-untitled-letter

The FDA just sent another untitled letter to a producer of a potentially non-compliant perinatal “stem cell” product that may be an unapproved drug. This follows past non-warning letters and/or inspection reports made public to Liveyon, R3 Stem Cell, Stemell, and others. RAPS has more on the story of the new letter here. This newest …

Another FDA letter to a stem cell clinic supplier: what’s the agency’s long game? Read More »